Ongoing monitoring and check-ins: body composition tracking, strength metrics, mobility, metabolic markers
Wang, Y., Chen, K., Cheng, G., Du, S
Based on early human studies and animal research, GLP-1 agonists may affect: Reward-related eating behaviours by potentially modulating dopamine signalling in brain reward circuits Food cravings and hedonic eating (eating for pleasure rather than hunger) Impulsivity around food , possibly reducing the compulsive aspects of eating Satiety signalling , enhancing the feeling of fullness after meals Some patients using GLP-1 medications for diabetes or weight management report not just reduced appetite but also diminished preoccupation with food, fewer intrusive thoughts about eating, and reduced cravings for specific foods, particularly those high in fat and sugar
Despite their popularity, there remains a paucity of human clinical evidence to support their safety and efficacy
Excellent choice of colors